Cartesian Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Cartesian Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.80M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $38.91M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $26.00M | Mar 13, 2025 |
| FY2016 | Dec 31, 2016 | $2.93M | Mar 28, 2017 |
| FY2016 | Sep 30, 2016 | $1.05M | Mar 28, 2017 |
| FY2016 | Jun 30, 2016 | $2.02M | Mar 28, 2017 |
| FY2016 | Mar 31, 2016 | $2.09M | Mar 28, 2017 |
| FY2016 | Dec 31, 2015 | $2.13M | Mar 28, 2017 |
| FY2016 | Sep 30, 2015 | $1.61M | Mar 28, 2017 |
| FY2016 | Jun 30, 2015 | $1.24M | Mar 28, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $400.0K | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $38.28M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $26.00M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $110.78M | Mar 7, 2024 |
| FY2023 | Dec 31, 2021 | $85.08M | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | $16.60M | Mar 2, 2023 |
| FY2019 | Dec 31, 2019 | $6.65M | Mar 12, 2020 |
| FY2019 | Sep 30, 2019 | $0 | Mar 12, 2020 |
| FY2019 | Jun 30, 2019 | $13.0K | Mar 12, 2020 |
| FY2019 | Mar 31, 2019 | $10.0K | Mar 12, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($130.30M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($77.42M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($219.71M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $35.38M | Mar 7, 2024 |
| FY2023 | Dec 31, 2021 | ($25.69M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | ($68.88M) | Mar 2, 2023 |
| FY2019 | Dec 31, 2019 | ($14.89M) | Mar 12, 2020 |
| FY2019 | Sep 30, 2019 | ($11.99M) | Mar 12, 2020 |
| FY2019 | Jun 30, 2019 | ($16.39M) | Mar 12, 2020 |
| FY2019 | Mar 31, 2019 | ($12.07M) | Mar 12, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($143.41M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($43.90M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($86.42M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $14.54M | Mar 7, 2024 |
| FY2023 | Dec 31, 2021 | ($4.60M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | ($56.82M) | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | ($52.46M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2018 | ($65.02M) | Mar 12, 2021 |
| FY2019 | Dec 31, 2017 | ($63.78M) | Mar 12, 2020 |
| FY2016 | Dec 31, 2016 | ($34.67M) | Mar 28, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $58.03M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $45.11M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $71.26M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $72.38M | Mar 7, 2024 |
| FY2023 | Dec 31, 2021 | $68.74M | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | $54.51M | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | $42.74M | Mar 10, 2022 |
| FY2020 | Dec 31, 2018 | $47.69M | Mar 12, 2021 |
| FY2019 | Dec 31, 2017 | $45.17M | Mar 12, 2020 |
| FY2016 | Dec 31, 2016 | $29.70M | Mar 28, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($73.94M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($23.67M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($51.16M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($31.63M) | Mar 7, 2024 |
| FY2023 | Dec 31, 2021 | ($60.38M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | $34.88M | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | ($51.44M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2018 | ($59.16M) | Mar 12, 2021 |
| FY2019 | Dec 31, 2017 | ($52.03M) | Mar 12, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.45M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $9.09M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $206.0K | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $1.20M | Mar 7, 2024 |
| FY2023 | Dec 31, 2021 | $1.09M | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | $815.0K | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | $47.0K | Mar 10, 2022 |
| FY2020 | Dec 31, 2018 | $884.0K | Mar 12, 2021 |
| FY2019 | Dec 31, 2017 | $733.0K | Mar 12, 2020 |
| FY2016 | Dec 31, 2016 | $586.0K | Mar 28, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $296.41M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $435.02M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $305.05M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $165.89M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $159.88M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $165.44M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $99.57M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $44.48M | Mar 12, 2020 |
| FY2016 | Dec 31, 2016 | $89.30M | Mar 28, 2017 |
| FY2016 | Dec 31, 2015 | $42.82M | Mar 28, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $422.65M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $441.83M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $444.68M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $72.06M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $137.36M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $183.44M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $91.17M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $49.90M | Mar 12, 2020 |
| FY2016 | Dec 31, 2016 | $34.34M | Mar 28, 2017 |
| FY2016 | Dec 31, 2015 | $21.84M | Mar 28, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($126.24M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($6.80M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | ($440.18M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | $93.83M | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | $22.52M | Mar 7, 2024 |
| FY2023 | Dec 31, 2020 | ($18.01M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2019 | $8.40M | Mar 2, 2023 |
| FY2021 | Dec 31, 2018 | ($5.42M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2017 | $51.81M | Mar 12, 2021 |
| FY2019 | Dec 31, 2016 | $54.96M | Mar 12, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.16M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $48.16M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $48.16M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Mar 7, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($822.37M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($692.07M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($614.65M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($394.94M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($430.32M) | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | ($404.63M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | ($335.75M) | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | ($280.40M) | Mar 12, 2020 |
| FY2016 | Dec 31, 2016 | ($151.58M) | Mar 28, 2017 |
| FY2016 | Dec 31, 2015 | ($111.51M) | Mar 28, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $125.14M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $212.61M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $76.91M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $106.44M | Mar 7, 2024 |
| FY2023 | Dec 31, 2021 | $114.06M | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | $138.69M | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | $89.89M | Mar 10, 2022 |
| FY2020 | Dec 31, 2018 | $37.40M | Mar 12, 2021 |
| FY2019 | Dec 31, 2017 | $70.62M | Mar 12, 2020 |
| FY2016 | Dec 31, 2016 | $58.66M | Mar 28, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (5) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | (49) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 7, 2024 |
| FY2023 | Dec 31, 2021 | 0 | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Mar 10, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (5) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | (49) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 7, 2024 |
| FY2023 | Dec 31, 2021 | 0 | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Mar 10, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 26.01M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | 25.77M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | 5.40M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | 153.04M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | 123.62M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | 108.07M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | 86.33M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | 22.47M | Mar 12, 2020 |
| FY2016 | Dec 31, 2016 | 18.44M | Mar 28, 2017 |
| FY2016 | Dec 31, 2015 | 2.17M | Mar 28, 2017 |